Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elismetrep - Kallyope

Next Previous
Search
Drug Profile

Elismetrep - Kallyope

Alternative Names: K-304; MT 8554

Latest Information Update: 19 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Kallyope; Mitsubishi Tanabe Pharma Corporation
  • Class Antimigraines; Benzoic acids; Cyclopropanes; Isoquinolines; Neuroprotectants; Small molecules; Sulfonamides
  • Mechanism of Action TRPM8 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Migraine; Vasomotor symptoms
  • No development reported Neurological disorders

Most Recent Events

  • 05 Mar 2025 Phase-II clinical trials in Migraine in USA (PO) (NCT06848075)
  • 26 Feb 2025 Kallyope plans a phase IIb trial for Acute Migraine (PO), in March 2025 (NCT06848075)
  • 27 Aug 2024 Kallyope has patent protection for Elismetrep in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top